# Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

> **NCT04749563** · PHASE1 · COMPLETED · sponsor: **IGC Pharma, LLC** · enrollment: 12 (actual)

## Conditions studied

- Dementia of Alzheimer Type

## Interventions

- **DRUG:** IGC AD1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04749563
- **Lead sponsor:** IGC Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2021-06-20
- **Final completion:** 2021-06-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04749563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04749563, "Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04749563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*